Department of Anesthesiology & Center for Brain Science, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, China.
School of Life Science and Technology, Xidian University, Xi'an, 710061, Shaanxi, China.
Neurochem Res. 2021 Jun;46(6):1410-1422. doi: 10.1007/s11064-021-03280-7. Epub 2021 Mar 3.
Propofol and dexmedetomidine are popular used for sedation in ICU, however, inadequate attention has been paid to their effect on gastrointestinal tract (GIT) motility. Present study aimed to compare the effect of propofol and dexmedetomidine on GIT motility at parallel level of sedation and explore the possible mechanism. Male C57BL/6 mice (8-10 weeks) were randomly divided into control, propofol and dexmedetomidine group. After intraperitoneal injection of propofol or dexmedetomidine, comparable sedative level was confirmed by sedative score, physiological parameters and electroencephalogram (EEG). Different segments of GIT motility in vivo (gastric emptying, small intestine transit, distal colon bead expulsion, stool weight and number of fecal pellets, gastrointestinal transit and whole gut transit time) and colonic migrating motor complexes (CMMCs) pattern in vitro were evaluated. The Ca response of primary enteric glia was examined under the treatment of propofol or dexmedetomidine. There is little difference in physiological parameters and composite permutation entropy index (CPEI) between administration of 50 mg/kg propofol and 40 μg/kg dexmedetomidine, indicated that parallel level of sedation was reached. Data showed that propofol and dexmedetomidine had significantly inhibitory effect on GIT motility while dexmedetomidine was stronger. Also, the amplitude (ΔF/F0) of Ca response in primary enteric glia was attenuated after treated with the sedatives while the effect of dexmedetomidine was greater than propofol. These findings demonstrated that dexmedetomidine caused stronger inhibitory effects on GIT motility in sedative mice, which may involve impaired Ca response in enteric glia. Hence, dexmedetomidine should be carefully applied especially for potential GIT dysmotility patient.
异丙酚和右美托咪定是 ICU 镇静中常用的药物,然而,人们对它们对胃肠道(GIT)动力的影响关注不足。本研究旨在比较异丙酚和右美托咪定在镇静水平相当的情况下对 GIT 动力的影响,并探讨其可能的机制。雄性 C57BL/6 小鼠(8-10 周)随机分为对照组、异丙酚组和右美托咪定组。腹腔注射异丙酚或右美托咪定后,通过镇静评分、生理参数和脑电图(EEG)确认相当的镇静水平。评估体内不同部位的 GIT 动力(胃排空、小肠转运、远端结肠珠排出、粪便重量和粪便颗粒数、胃肠转运和全肠道转运时间)和体外结肠移行性运动复合波(CMMCs)模式。在异丙酚或右美托咪定处理下,观察原代肠胶质细胞的 Ca 反应。给予 50mg/kg 异丙酚和 40μg/kg 右美托咪定时,生理参数和复合排列熵指数(CPEI)差异较小,表明达到了镇静水平相当的效果。结果表明,异丙酚和右美托咪定对 GIT 动力均有明显的抑制作用,而右美托咪定的抑制作用更强。此外,用镇静剂处理后,原代肠胶质细胞的 Ca 反应幅度(ΔF/F0)减弱,而右美托咪定的作用大于异丙酚。这些发现表明,右美托咪定在镇静小鼠中对 GIT 动力产生更强的抑制作用,这可能涉及肠胶质细胞 Ca 反应受损。因此,右美托咪定应谨慎应用,特别是对潜在的 GIT 动力障碍患者。